Phase II trials of mitomycin C, AB-100, NSC-1026, L-sarcolysin, and meta-sarcolysin, in the treatment of multiple myeloma.
D000900:Anti-Bacterial Agents / Q000628:therapy*; D000970:Antineoplastic Agents / Q000628:therapy*; D064987:Cell- and Tissue-Based Therapy; D003515:Cycloleucine; D003516:Cycloparaffins / Q000628:therapy*; D008558:Melphalan; D016685:Mitomycin; D009101:Multiple Myeloma / Q000628:therapy*; D010949:Plasma; D010950:Plasma Cells
D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D003516:Cycloparaffins; D003515:Cycloleucine; D016685:Mitomycin; D008558:Melphalan
ANTIBIOTICS/therapy; ANTINEOPLASTIC AGENTS/therapy; CYCLOPARAFFINS/therapy; MYELOMA, PLASMA CELL/therapy